Literature DB >> 18180358

In vitro activity of AR-709 against Streptococcus pneumoniae.

W T M Jansen1, A Verel, J Verhoef, D Milatovic.   

Abstract

We investigated the in vitro activity of AR-709, a novel diaminopyrimidine antibiotic currently in development for treatment of community-acquired upper and lower respiratory tract infections, against 151 Streptococcus pneumoniae strains from various European countries. AR-709 showed excellent activity against both drug-susceptible and multidrug-resistant pneumococci.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18180358      PMCID： PMC2258511          DOI： 10.1128/AAC.01332-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  1 in total

Review 1.  Dihydrofolate reductase inhibitors as antibacterial agents.

Authors:  Stephen Hawser; Sergio Lociuro; Khalid Islam
Journal:  Biochem Pharmacol       Date:  2005-12-13       Impact factor: 5.858
  1 in total
  2 in total

1.  Antistreptococcal activity of AR-709 compared to that of other agents.

Authors:  Kathy Smith; Lois M Ednie; Peter C Appelbaum; Stephen Hawser; Sergio Lociuro
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

2.  A microdose study of ¹⁴C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung.

Authors:  G Lappin; M J Boyce; T Matzow; S Lociuro; M Seymour; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  2013-06-06       Impact factor: 2.953
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.